Figure 4: Time to First Occurrence of Hospitalization for Heart Failure or CV Death in the DECLARE Trial Figure 5: Time to First Occurrence of Hospitalization for Heart Failure in the DECLARE Trial 14.4 Chronic Kidney Disease The Trial to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients with Chronic Kidney Disease (DAPA-CKD, NCT03036150) was an international, multicenter, randomized, double-blind, placebo-controlled trial in adult patients with chronic kidney disease (CKD) (eGFR between 25 and 75 mL/min/1.73 m2) and albuminuria [urine albumin creatinine ratio (UACR) between 200 and 5000 mg/g] who were receiving standard of care background therapy, including a maximally tolerated, labeled daily dosage of an angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB)
When our friend of SOS and contributing nutrition editor, Sarah Wragge, recently posted on Instagram about the responsibility that comes with taking these drugs, we decided it was time to dig in and have a conversation about GLP-1s SARAH WRAGGE: Im excited to do this with you because I want to be very public about how often on a daily basis I am talking about GLPs
10.1038/s41580-020-00317-7 16 CantiniG.MannucciE.LuconiM
Adems, la aplicacin semanal es una ventaja relacionada a la adherencia al tratamiento y calidad de vida por la disminucin de los pinchazos
Although an association with urinary congenital malformations was identified, it was based on limited unadjusted data and may reflect confounding by maternal diabetes or obesity rather than a true treatment effect
Source: Californiaherps Cute huh
